Market Overview

Mizuho: Samsung Bioepis Renegotiation 'A Positive' For Biogen

Mizuho: Samsung Bioepis Renegotiation 'A Positive' For Biogen
Related BIIB
Wells Fargo Bullish On Applied Genetic Technologies Ahead Of Program Update
The Daily Biotech Pulse: Adverum Snags Fast Track Designation, Crispr To Offer Shares, Elanco Animal Health To Debut
Can Biogen Continue to Be a Top Performer in the Biotech Space? (GuruFocus)

Samsung Group is reportedly in talks to buy at least 30 percent of Biogen Inc (NASDAQ: BIIB)’s stake in Samsung Bioepis, which could drive upside to the seller’s stock.

The Rating

Mizuho Securities analyst Salim Syed maintained a Buy rating on Biogen with a $433 price target.

The Thesis

Samsung BioLogics and Biogen, which together established the biopharma company Samsung Bioepis as a joint venture in 2011, currently hold respective 94.6-percent and 5.4-percent stakes in the entity, but Biogen also owns a call option allowing it to increase ownership to 49.9 percent by the end of June.

If Biogen exercises its right, as it has previously said it would do, Business Korea estimates it could cost about $421.35 million.

At the same time, Samsung Group is said to be prepared to spend $2.81 billion to purchase a portion of Biogen’s stake.

“If the article's numbers are accurate [...] the renegotiation would be a positive for BIIB in our view,” Syed said in a Wednesday note.

Regardless of whether Biogen sells or buys, it’s seen to incrementally boost its value. Syed forecasts the sell-or-buy scenario could drive 4-8-percent upside to the stock.

Price Action

Despite the news first breaking Monday, Biogen’s stock trended higher Wednesday and was up about 1.5 percent at the time of publication. 

Related Links:

Argus Downgrades Biogen On Trial Delays, Competition In MS, Alzheimer's Drugs

BofA: The Biotech Sector Is In A 'Perfect Storm' For M&A

Latest Ratings for BIIB

Aug 2018Stifel NicolausReinstatesBuy
Jul 2018UBSMaintainsBuyBuy
Jul 2018BarclaysMaintainsEqual-WeightEqual-Weight

View More Analyst Ratings for BIIB
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Price Target Reiteration Top Stories Analyst Ratings Media General Best of Benzinga


Related Articles (BIIB)

View Comments and Join the Discussion!

Mid-Day Market Update: Analogic Falls Following Acquisition News; EyeGate Pharmaceuticals Shares Gain

Opticals Taking Back Lost Market Share, According To Rosenblatt